[Severe thrombocytopenia associated with Abciximab therapy--apropos a clinical case].
The authors present the case of a 52-year-old male patient with severe coronary artery disease, submitted to percutaneous transluminal coronary angioplasty on a type C right coronary artery lesion. The use of a platelet glycoprotein receptor IIb-IIIa inhibitor, Abciximab, led to severe thrombocytopenia, treated only with platelet concentrate transfusions and with complete recovery. We also review the principal characteristics of the drug, its main indications and side effects. Severe thrombocytopenia has rarely been described in the literature.
Mendes
V
V
Unidade de Cuidados Intensivos Médicos, Hospital de São Francisco Xavier, Lisboa.
Resende
M
M
Santos
J M
JM
Mourão
L
L
Santos
A L
AL
Luís
A S
AS
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D012008:Recurrence; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab